Retroscreen Virology Group PLC Board Change (1652M)
14 Juillet 2014 - 8:00AM
UK Regulatory
TIDMRVG
RNS Number : 1652M
Retroscreen Virology Group PLC
14 July 2014
For immediate release 07.00: 14 July 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
BOARD CHANGE
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO
human challenge models of disease, is pleased to announce that Dr
Alison Fielding has been appointed as a Non-Executive Director of
the Company with immediate effect.
Alison is a highly respected, entrepreneurial leader, executive
coach and mentor with extensive board experience in both Executive
and Non-Executive capacities in public, private and not-for-profit
sectors. She has a track record of creating and building
high-performing companies based on scientific innovation.
Alison is Director of IP Impact at IP Group plc, a leading UK
intellectual property commercialisation company. She co-founded
Techtran Group Limited and was the Chief Operating Officer of
Techtran when it was acquired by IP Group in January 2005. She was
a Director of IP Group from January 2005 to June 2013, promoted to
Chief Technology officer in March 2007 and then Chief Operating
Officer in May 2011. She spent six years at McKinsey & Co from
1994 to 2000, where she consulted primarily to the pharmaceutical
and health care sectors. Prior to McKinsey, she spent four years as
a development chemist for Zeneca, performing technical roles in the
speciality chemicals and agrochemicals divisions. Alison holds an
MBA from Manchester Business School, a Ph.D. in Organic Chemistry
and a first class degree in Chemistry from the University of
Glasgow.
Kym Denny, Chief Executive Officer, commented, "I am delighted
to welcome Alison to Retroscreen's newly shaped Board, at this
exciting juncture in the Company's development. Alison has a
tremendous track record of working with growth companies in the
life science sector to achieve their potential. We look forward to
benefitting from her expertise, as we actively broaden
Retroscreen's capabilities in our quest to leverage fully our
unique hVIVO technology platform."
Dr Alison Margaret Fielding (49) is a director/ partner or has
been a director/ partner of the following companies/ partnerships
during the previous five years:
Current
Getech Group plc
Green Chemicals plc
Perachem Limited
Tissue Regenix Group plc
Previous
Amaethon Limited
Amaethon Trustees Limited
Care International UK
COE Group plc
Crysalin Limited
Fusion IP plc
IP Group Plc
IP2IPO Limited
IP2IPO Services Limited
IP Industry Partners Limited
Techtran Group Limited
Techtran Limited
Techtran Corporate Finance Limited
Techtran Investments Limited
Techtran Services Limited
Pure Polymers Limited
Top Technology Ventures Limited
The Foundation for Social Entrepreneurs
Dr Fielding holds 24,320 ordinary shares in the Company, which
were acquired prior to the Company's IPO in May 2012.
Save for the information disclosed above there is no other
information to be disclosed on Dr Fielding under Schedule 2(g) of
the AIM Rules.
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
Retroscreen Virology Group plc ("Retroscreen") is a rapidly
growing UK life sciences company pioneering a technology platform
called hVIVO which uses human models of disease involving healthy
volunteers to study new drugs and investigate disease in a safe,
controlled environment.
Retroscreen has established itself as the world leader in this
field through the provision of clinical services to third party
study sponsors. To date, the Company has conducted over 35 clinical
studies, involving more than 1600 volunteers for a range of leading
industry, governmental and academic clients.
However, Retroscreen's hVIVO platform has a much wider
application in helping to understand illness better because the
Company believes that the best way to understand human disease is
by studying it in humans, not laboratory models.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAQKDDQOBKDPOD
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024